Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Neoplasms 9Carcinoma, Non-Small-Cell Lung 6Recurrence 5Hematologic Neoplasms 5Breast Neoplasms 5Neoplasm Metastasis 4Advanced Solid Tumors 4Solid Tumor 3Melanoma 3Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia, Myeloid, Acute 3Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Neutropenia 2Medical Oncology 2Lymphoma, Follicular 2Esophageal Squamous Cell Carcinoma 2Endometrial Neoplasms 2Biliary Tract Neoplasms 2Tuberous Sclerosis 1Solid Tumours 1Solid Tumour 1Solid Tumors 1Solid Tumor, Adult 1

Interventions

Cyclophosphamide 17blinatumomab 16fludarabine 13Vincristine 11Cytarabine 10tisagenlecleucel 8pegaspargase 8nilotinib 8Methotrexate 8Inotuzumab Ozogamicin 8Clofarabine 8venetoclax 7Dexamethasone 7asparaginase erwinia chrysanthemi recombinant 6Dasatinib 6Azacitidine 5AP 1903 reagent 5aflibercept 4Mercaptopurine 4Imatinib Mesylate 4Filgrastim 4Etoposide 4Drug Therapy 4Daunorubicin 4ponatinib 3Sensitivity and Specificity 3Mitoxantrone 3Immunotherapy, Adoptive 3Granulocyte Colony-Stimulating Factor 3CPX-351 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Itraconazole × Clear all
NCT04067336 2026-05-13

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Kura Oncology, Inc.

Phase 1/2 Active not recruiting
263 enrolled 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡